Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

Pierre Amarenco; Larry B Goldstein; Henrik Sillesen; Oscar Benavente; Richard M Zweifler; Alfred Callahan; Michael G Hennerici; Justin A Zivin; K Michael A Welch; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators

doi:10.1161/STROKEAHA.109.564781

Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

Pierre Amarenco, Larry B Goldstein, Henrik Sillesen, Oscar Benavente, Richard M Zweifler, Alfred Callahan, Michael G Hennerici, Justin A Zivin, K Michael A Welch, Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators

52 Citationer (Scopus)

Abstract

Noncoronary forms of atherosclerosis (including transient ischemic attacks or stroke of carotid origin or >50% stenosis of the carotid artery) are associated with a 10-year vascular risk of >20% and are considered as a coronary heart disease (CHD) -risk equivalent from the standpoint of lipid management. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial included patients with stroke or transient ischemic attack and no known CHD regardless of the presence of carotid atherosclerosis. We evaluated the risk of developing clinically recognized CHD in SPARCL patients.

Originalsprog	Engelsk
Tidsskrift	Stroke
Vol/bind	41
Udgave nummer	3
Sider (fra-til)	426-30
Antal sider	5
ISSN	0039-2499
DOI	https://doi.org/10.1161/STROKEAHA.109.564781
Status	Udgivet - 1 mar. 2010

Adgang til dokumentet

10.1161/STROKEAHA.109.564781

Fingeraftryk

Dyk ned i forskningsemnerne om 'Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Amarenco, P., Goldstein, L. B., Sillesen, H., Benavente, O., Zweifler, R. M., Callahan, A., Hennerici, M. G., Zivin, J. A., Welch, K. M. A., & Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators (2010). Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke, 41(3), 426-30. https://doi.org/10.1161/STROKEAHA.109.564781

Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. / Amarenco, Pierre; Goldstein, Larry B; Sillesen, Henrik et al.
I: Stroke, Bind 41, Nr. 3, 01.03.2010, s. 426-30.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Amarenco, P, Goldstein, LB, Sillesen, H, Benavente, O, Zweifler, RM, Callahan, A, Hennerici, MG, Zivin, JA, Welch, KMA & Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators 2010, 'Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial', Stroke, bind 41, nr. 3, s. 426-30. https://doi.org/10.1161/STROKEAHA.109.564781

@article{099fd9d9da2341f5b63b28ee81bf1ec7,

title = "Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial",

abstract = "Noncoronary forms of atherosclerosis (including transient ischemic attacks or stroke of carotid origin or >50% stenosis of the carotid artery) are associated with a 10-year vascular risk of >20% and are considered as a coronary heart disease (CHD) -risk equivalent from the standpoint of lipid management. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial included patients with stroke or transient ischemic attack and no known CHD regardless of the presence of carotid atherosclerosis. We evaluated the risk of developing clinically recognized CHD in SPARCL patients.",

author = "Pierre Amarenco and Goldstein, {Larry B} and Henrik Sillesen and Oscar Benavente and Zweifler, {Richard M} and Alfred Callahan and Hennerici, {Michael G} and Zivin, {Justin A} and Welch, {K Michael A} and {Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators}",

year = "2010",

month = mar,

day = "1",

doi = "10.1161/STROKEAHA.109.564781",

language = "English",

volume = "41",

pages = "426--30",

journal = "Stroke",

issn = "0039-2499",

publisher = "Wolters Kluwer Health",

number = "3",

}

TY - JOUR

T1 - Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

AU - Amarenco, Pierre

AU - Goldstein, Larry B

AU - Sillesen, Henrik

AU - Benavente, Oscar

AU - Zweifler, Richard M

AU - Callahan, Alfred

AU - Hennerici, Michael G

AU - Zivin, Justin A

AU - Welch, K Michael A

AU - Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Noncoronary forms of atherosclerosis (including transient ischemic attacks or stroke of carotid origin or >50% stenosis of the carotid artery) are associated with a 10-year vascular risk of >20% and are considered as a coronary heart disease (CHD) -risk equivalent from the standpoint of lipid management. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial included patients with stroke or transient ischemic attack and no known CHD regardless of the presence of carotid atherosclerosis. We evaluated the risk of developing clinically recognized CHD in SPARCL patients.

AB - Noncoronary forms of atherosclerosis (including transient ischemic attacks or stroke of carotid origin or >50% stenosis of the carotid artery) are associated with a 10-year vascular risk of >20% and are considered as a coronary heart disease (CHD) -risk equivalent from the standpoint of lipid management. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial included patients with stroke or transient ischemic attack and no known CHD regardless of the presence of carotid atherosclerosis. We evaluated the risk of developing clinically recognized CHD in SPARCL patients.

U2 - 10.1161/STROKEAHA.109.564781

DO - 10.1161/STROKEAHA.109.564781

M3 - Journal article

C2 - 20110538

SN - 0039-2499

VL - 41

SP - 426

EP - 430

JO - Stroke

JF - Stroke

IS - 3

ER -